Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.46 |
| ▸ | KRAS | P01116 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29765709 | 1.00 | KIT (0.53) | KITCNR1CNR2PDGFRBPDGFRA | |
| SCHEMBL29765786 | 0.92 | KIT (0.63) | KITCNR1CNR2PDGFRBKRAS | |
| SCHEMBL16637005 | 0.92 | KIT (0.63) | KITCNR1CNR2PDGFRBKRAS | |
| SCHEMBL16647248 | 0.89 | KIT (0.63) | KITCNR1CNR2PDGFRBKRAS | |
| SCHEMBL16636967 | 0.86 | CNR1 (0.57) | KITCNR1CNR2PDGFRBPDGFRA | |
| SCHEMBL16647170 | 0.86 | TLR9 (0.49) | KITCNR1CNR2MEN1KMT2A | |
| SCHEMBL16637135 | 0.85 | TLR9 (0.48) | KITCNR1CNR2MEN1KMT2A | |
| SCHEMBL16637349 | 0.85 | PDGFRB (0.52) | KITPDGFRBPDGFRAAKT1KRAS | |
| SCHEMBL16637261 | 0.84 | TLR9 (0.51) | CNR1CNR2MEN1KMT2ARET | |
| SCHEMBL16636796 | 0.84 | CNR1 (0.41) | KITCNR1CNR2PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20220242875-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2022-08-04 | — | — | US | disclosed |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2021-06-24 | — | — | US | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3193851-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | Araxes Pharma LLC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| WO-2016049568-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016044772-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | KIT 1512/4885CNR1 4561/4885CNR2 4681/4885 |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KIT 4380/4885CNR1 3222/4885CNR2 4236/4885 |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KIT 3011/4885CNR1 590/4885CNR2 1691/4885 |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KIT 4086/4885CNR1 3613/4885CNR2 4274/4885 |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KIT 3330/4885CNR1 2883/4885CNR2 3665/4885 |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KIT 3330/4885CNR1 2883/4885CNR2 3665/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KIT 4380/4885CNR1 3222/4885CNR2 4236/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KIT 4380/4885CNR1 3222/4885CNR2 4236/4885 |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KIT 4380/4885CNR1 3222/4885CNR2 4236/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KIT 4380/4885CNR1 3222/4885CNR2 4236/4885 |
| US-20220242875-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KIT 4380/4885CNR1 3222/4885CNR2 4236/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | KIT 2636/4885CNR1 4396/4885CNR2 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.